NCT07139990 Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
| NCT ID | NCT07139990 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | Small Cell Lung Cancer Extensive Stage |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2025-10-28 |
| Primary Completion | 2028-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 45 participants in total. It began in 2025-10-28 with a primary completion date of 2028-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
Eligibility Criteria
Inclusion Criteria: Cohort A: * \>=18 years old * Performance status ECOG 0-2 * Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration. * Patient must be planned for or receiving standard of care chemoimmunotherapy. * Patient must have received no more than 3 cycles by time of study enrollment. * Able and indicated according to investigator to receive thoracic radiotherapy Cohort B: * 18 years old * Diagnosis of solid tumor malignancy with MRI-defined brain metastasis lesions (1-5 lesions allowed) within 60 days of registration * Each brain metastasis lesion enrolled must be 2 - 5 cm, except brainstem lesions which may be 1.5 - 5cm in size. Exclusion Criteria: Cohort A: ⨀ Prior thoracic Radiotherapy Cohort B: * Prior whole brain Radiotherapy * Prior surgical resection or focal radiotherapy of a target brain metastasis * Leptomeningeal disease
Contact & Investigator
NEIL DESAI, MD, MHS
PRINCIPAL INVESTIGATOR
University of Texas Southwestern Medical Center
Frequently Asked Questions
Who can join the NCT07139990 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Small Cell Lung Cancer Extensive Stage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07139990 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07139990 currently recruiting?
Yes, NCT07139990 is actively recruiting participants. Contact the research team at Sarah.Hardee@UTSouthwestern.edu for enrollment information.
Where is the NCT07139990 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT07139990 clinical trial?
NCT07139990 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is NEIL DESAI, MD, MHS at University of Texas Southwestern Medical Center. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.